CEPHEID
Healthcare · Laboratory Analytical Instruments · CA · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | |
|---|---|---|---|---|---|---|
| Revenue | $132.6M | $106.9M | $401.3M | $331.2M | $277.6M | $212.5M |
| Operating income | $4.6M | −$6.3M | −$16.0M | −$21.3M | $3.8M | −$5.3M |
| Net income | $906,000 | −$9.3M | −$18.0M | −$20.0M | $2.6M | −$5.9M |
| Total assets | $821.6M | $793.6M | $394.6M | $331.5M | $286.7M | $220.6M |
| Total liabilities | $451.7M | $439.4M | $109.4M | $84.0M | $74.8M | $66.9M |
| Equity | $370.0M | $354.2M | $285.2M | $247.5M | $211.8M | $153.7M |
| EPS (diluted) | $0.01 | $-0.13 | $-0.27 | $-0.30 | $0.04 | $-0.10 |
| Shares out. | 71.3M | 69.4M | 66.8M | 65.2M | 61.1M | 60.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2015- Operating margin
- 3.5%
- Net margin
- 0.7%
- Return on equity
- 0.2%
- Return on assets
- 0.1%
- Return on capital (ROCE)
- 0.7%
- Liabilities / assets
- 55.0%
- Debt / equity
- 1.22×
- Book value / share
- $5.19
- Revenue growth (YoY)
- 24.1%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2015- Altman Z″ (distress)
- 2.85safe
- Accruals / assets
- −3.7%clean
- Beneish M-Score
- -2.74normal
- Piotroski F-Score
- 8/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 5 good- Operating margin is positive
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Debt acceleration / triggering event · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Shareholder voteNov 7, 2016
- Director / officer changeOct 28, 2016
- Other material eventOct 24, 2016
- Entered a material agreement · Amended charter or bylaws · Other material eventSep 6, 2016
- Entered a material agreement · Director / officer changeAug 1, 2016
- Results of operationsJul 28, 2016
- Results of operationsApr 28, 2016
- Shareholder voteApr 27, 2016
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/ACEPHEID 13G AMENDMENT 1Feb 7, 2017
- CT ORDERNov 17, 2016
- 15-12GNov 17, 2016
- 4/AFORM 4/A SUBMISSIONNov 7, 2016
- 4FORM 4 SUBMISSIONNov 7, 2016
- 4FORM 4 SUBMISSIONNov 7, 2016
- 4FORM 4 SUBMISSIONNov 7, 2016
- 4FORM 4 SUBMISSIONNov 7, 2016
- 4FORM 4 SUBMISSIONNov 7, 2016
- 4FORM 4 SUBMISSIONNov 7, 2016
- 4FORM 4 SUBMISSIONNov 7, 2016
- 4FORM 4 SUBMISSIONNov 7, 2016
- 4FORM 4 SUBMISSIONNov 7, 2016
- 4FORM 4 SUBMISSIONNov 7, 2016
- 4FORM 4 SUBMISSIONNov 7, 2016